Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

QOMS Another step along the way.

The British journal of oral & maxillofacial surgery·2026
Same author

Challenges in analyzing real-world evidence: analysis of androgen deprivation therapy use for prostate cancer in the REASSURE study.

ESMO real world data and digital oncology·2026
Same author

Alumni-Informed Curriculum in Pediatric Dentistry: Narratives from a Quality Improvement Evaluation.

JDR clinical and translational research·2025
Same author

Outcomes Assessment of a Predoctoral Pediatric Dentistry Clinical Rotation Using Alumni Surveys.

JDR clinical and translational research·2025
Same author

Youth screen use in the ABCD® study.

Developmental cognitive neuroscience·2022
Same author

BAOMS QOMS: findings from the pilot phase and lessons learned in the feasibility evaluation of a national quality improvement initiative.

The British journal of oral & maxillofacial surgery·2021

Related Experiment Video

Updated: May 21, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

New developments in castrate-resistant prostate cancer.

N Shore1, M Mason, Th M de Reijke

  • 1Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC 29572, USA. nshore@gsuro.com

BJU International
|June 8, 2012
PubMed
Summary
This summary is machine-generated.

New treatments for castrate-resistant prostate cancer (CRPC) offer more options. These include immunotherapies, hormone biosynthesis inhibitors, and targeted therapies, improving the CRPC treatment landscape.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Experiment Videos

Last Updated: May 21, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Area of Science:

  • Oncology
  • Urology

Background:

  • Castrate-resistant prostate cancer (CRPC) is prostate cancer that progresses despite low androgen levels.
  • Historically, docetaxel was the primary treatment for metastatic CRPC.
  • Recent advancements have introduced new therapeutic classes for CRPC management.

Purpose of the Study:

  • To review current and emerging treatment options for castrate-resistant prostate cancer.
  • To discuss the mechanisms of action for novel CRPC therapeutics.
  • To consider the potential role of new agents in the CRPC treatment landscape.

Main Methods:

  • Review of recently approved and investigational agents for CRPC.
  • Discussion of therapeutic mechanisms, including immunotherapy, hormonal manipulation, and targeted therapies.
  • Analysis of ongoing Phase III clinical trials for metastatic CRPC.

Main Results:

  • Sipuleucel-T (immunotherapy) approved for non-metastatic CRPC.
  • Abiraterone (androgen biosynthesis inhibitor) and cabazitaxel (chemotherapy) approved for metastatic CRPC.
  • Denosumab (antibody) and zoledronic acid (bisphosphonate) options for bone metastases.
  • Numerous targeted therapies and immunotherapies in late-stage development.

Conclusions:

  • The treatment landscape for CRPC has significantly expanded beyond traditional chemotherapy.
  • Emerging therapies target androgen receptor pathways, immune responses, and specific molecular targets.
  • Further research and clinical trials are evaluating the efficacy and optimal sequencing of these novel agents in CRPC management.